Mostrar el registro sencillo del ítem
dc.contributor.author | Falcon-Neyra, Lola | |
dc.contributor.author | Palladino, Claudia | |
dc.contributor.author | Navarro Gómez, María Luisa | |
dc.contributor.author | Soler-Palacín, Pere | |
dc.contributor.author | González-Tomé, María Isabel | |
dc.contributor.author | De Ory, Santiago J | |
dc.contributor.author | Frick, Marie Antoinette | |
dc.contributor.author | Fortuny, Clàudia | |
dc.contributor.author | Noguera-Julian, Antoni | |
dc.contributor.author | Moreno, Elena Bermúdez | |
dc.contributor.author | Santos, Juan Luis | |
dc.contributor.author | Olbrich, Peter | |
dc.contributor.author | López-Cortés, Luis F | |
dc.contributor.author | Briz, Veronica | |
dc.contributor.author | Neth, Olaf | |
dc.date.accessioned | 2020-04-21T08:39:06Z | |
dc.date.available | 2020-04-21T08:39:06Z | |
dc.date.issued | 2016-06 | |
dc.identifier.citation | Medicine (Baltimore) . 2016 Jun;95(24):e3842. | es_ES |
dc.identifier.issn | 0025-7974 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/9641 | |
dc.description.abstract | To assess the safety and efficacy of rilpivirine in combination with emtricitabine and tenofovir (RPV/FTC/TDF) as a once-daily single-tablet regimen (STR) in HIV-1-infected children and adolescents we performed a multicenter case series study of HIV-1-infected patients. Inclusion criteria were initiation of therapy with RPV/FTC/TDF before the age of 18. Patients were divided into undetectable viral load (uVL) group, HIV-1 RNA < 20 copies/mL on stable combined antiretroviral therapy (cART), and detectable viral load (dVL) group, HIV-1 RNA ≥ 20 copies/mL at RPV/FTC/TDF initiation. Patients were monitored from the date of RPV/FTC/TDF initiation until June 30, 2015, RPV/FTC/TDF discontinuation or failure to follow-up. Seventeen patients (8 in uVL and 9 in dVL group) with age between 11.6 and 17.6 were included. Reasons for switching were toxicity (n = 4) and simplification (n = 4) in uVL; viral failure (n = 8) and cART initiation (n = 1) in the dVL group. After a median follow-up of 90 (uVL) and 40 weeks (dVL), 7/8 (86%) patients maintained and 8/9 (89%) achieved and maintained HIV-1 suppression. Median CD4 count increased from 542 to 780/μL (uVL, P = 0.069) and 480 to 830/μL (dVL, P = 0.051). Five patients (2 in uVL and 3 in dVL) improved their immunological status from moderate to no immunosuppression. Serum lipid profiles improved in both groups; cholesterol dropped significantly in the dVL group (P = 0.008). Grade 1 laboratory adverse events (AEs) were observed in 3 patients. No clinical AEs occurred. Adherence was complete in 9 patients (5 in uVL and 4 in dVL); 1 adolescent interrupted treatment. Once-daily STR with RPV/FTC/TDF may be a safe and effective choice in selected HIV-1-infected adolescents and children. | es_ES |
dc.description.sponsorship | Financial support was provided by the Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida (ISCIII-RETIC RD06/006; RD12/0017/0035, and RD12/0017/0037) and FIPSE (grant number: 36-0910-10). This work has been also supported by grants from Instituto de Salud Carlos III (Ref. MPY 1039/14 to VB). CP is supported by the Portuguese Fundação para a Ciência e Tecnologia (FCT) (grant number SFRH/BPD/77448/2011, part of the EDCTP2 program supported by the European Union). VB is supported by the Miguel Servet program run by the Fondo de Investigación Sanitaria (ISCIII) (grant number CP13/00098). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Lippincott Williams & Wilkins (LWW) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.mesh | Adolescent | es_ES |
dc.subject.mesh | Anti-HIV Agents | es_ES |
dc.subject.mesh | Child | es_ES |
dc.subject.mesh | Drug Therapy, Combination | es_ES |
dc.subject.mesh | Emtricitabine | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Follow-Up Studies | es_ES |
dc.subject.mesh | HIV Infections | es_ES |
dc.subject.mesh | HIV-1 | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Off-Label Use | es_ES |
dc.subject.mesh | RNA, Viral | es_ES |
dc.subject.mesh | Retrospective Studies | es_ES |
dc.subject.mesh | Tenofovir | es_ES |
dc.subject.mesh | Treatment Outcome | es_ES |
dc.title | Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 27310962 | es_ES |
dc.format.volume | 95 | es_ES |
dc.format.number | 24 | es_ES |
dc.format.page | e3842 | es_ES |
dc.identifier.doi | 10.1097/MD.0000000000003842 | es_ES |
dc.contributor.funder | Red de Investigación Cooperativa en Investigación en Sida (España) | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | Fundação para a Ciência e Tecnologia (Portugal) | |
dc.description.peerreviewed | No | es_ES |
dc.identifier.e-issn | 1536-5964 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1097/MD.0000000000003842 | es_ES |
dc.identifier.journal | Medicine | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/ISCIII-RETIC RD06/006 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/RD12/0017/0035, | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/RD12/0017/0037 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/36-0910-10 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/MPY 1039/14 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/SFRH/BPD/77448/2011 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/CP13/00098 | es_ES |
dc.rights.accessRights | open access | es_ES |